Sun Pharma in race to acquire InSite Vision?

By: |
New Delhi | September 15, 2015 8:55 PM

Drug major Sun Pharmaceutical Industries is said to be in race to acquire US-based eye care firm InSite Vision Inc at a price of $0.35 per share.

sun pharma profitInSite’s Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock. (Reuters)

Drug major Sun Pharmaceutical Industries is said to be in race to acquire US-based eye care firm InSite Vision Inc at a price of $0.35 per share.

“InSite’s Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at USD 0.35 per share in an all- cash transaction constitutes a ‘Company Superior Proposal’ as defined in InSite’s previously announced definitive agreement with QLT Inc dated as of August 26, 2015,” the US-based company said.

The company, however, did not name the suitor but reports suggested it was Sun Pharmaceuticals.

Earlier in August, InSite Vision announced a definite agreement with drug firm QLT.

InSite has notified QLT of the InSite Board of Directors’ determination and will engage in discussions with the Bidder, it added.

“Under the QLT merger agreement, InSite would be required to pay a USD 2,667,000 termination fee to QLT if the InSite Board of Directors terminates the QLT merger agreement in favour of an agreement with the Bidder. The Bidder has agreed to pay the termination fee to QLT on InSite’s behalf in such event,” InSite said.

When contacted a Sun Pharma spokesperson said: “We don’t comment on market speculations.” On the other hand, a reply from InSite Vision could not be obtained by the time of filing the story.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1ArcelorMIttal posts $2,285 million net income in March quarter
2HC seeks CCI stand on Facebook, WhatsApp appeals against single judge order on privacy policy
3If India is in dire straits, then world is in dire straits, says USIBC president